Strategies to Ramp up Manufacturing to Meet Global Needs

coronovirus in conversation banner

Strategies to Ramp Up Manufacturing to Meet Global Needs

As the number of SARS-CoV-2 cases exceed 9 million and vaccine development efforts are ramped up, organizations are moving from pre-clinical into phase 1 and 2 studies at unprecedented speed. With foresight, many have begun preparing for large-scale manufacturing by ensuring sufficient capacity to meet global demand. As part of the Corona360 – In Conversation series, the “Strategies to Ramp up Manufacturing to meet the Global Needs” live moderated discussion aims at addressing these obstacles and solutions by companies in preparation for global manufacturing of SARS-CoV-2 vaccines.

Interview Details

23rd July 2020, Thursday

15:30:00 (GMT +8:00)

Register Now

Add to Calendar

  • Process development, manufacturing, production, operations & facility heads and professionals working on SARS-CoV-2 vaccine development from BIG Pharmas, vaccine manufacturers and research institutions.
  • CMOs, technology / service providers and logistics partners keen on understanding how they can alleviate the challenges faced in the manufacturing value chain.
  • Strategies to address SARS-CoV-2 vaccine large scale manufacturing challenges from the get-go.
  • How CMOs, technology / service providers and other industry stakeholders may step in to fill the gaps in SARS-CoV-2 vaccine manufacturing demand.
  • Recommendations on how lessons learnt from this experience can be applied to other emerging infectious diseases and future pandemics.

Meet Our Silver Sponsor

Meet Our Esteemed Panelists

Koh Sok Tiang, VP Scientific Affairs & Technical Services APAC, West Pharmaceutical Services

Ashish Sahai, Director – Viral Vaccines, Serum Institute of India

Li Shi, Chief Scientific Advisor, Former CEO, Shanghai Zerun Biotechnology

Ashley Lauren St. John, Associate Professor, Duke-NUS Medical School

Key Discussion Points

  • Reducing process development timelines to a couple of months from a year scale-up plan for COVID-19 vaccines.
  • Most of the lead developers in the COVID-19 vaccine race are small and/or inexperienced in large-scale vaccine manufacture.
  • What are some of the strategies that could be worked on to ensure co-ordination of vaccine manufacturing and supply chain capability and capacity to meet the demand?

Market Intelligence